Seres Therapeutics Files 8-K Report
Ticker: MCRB · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting
TL;DR
Seres Therapeutics filed an 8-K, likely for shareholder votes and financial updates.
AI Summary
On September 26, 2024, Seres Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The filing does not contain specific financial figures or details about the matters to be voted on, but indicates a formal reporting event.
Why It Matters
This filing signals a formal corporate event requiring shareholder or regulatory attention, potentially related to governance or financial updates.
Risk Assessment
Risk Level: low — The filing is a routine procedural report and does not disclose new material financial or operational risks.
Key Numbers
- 001-37465 — Commission File Number (Identifier for Seres Therapeutics' SEC filings)
- 27-4326290 — IRS Employer Identification No. (Tax identification number for Seres Therapeutics)
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Registrant
- September 26, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, MA (location) — Address of principal executive offices
FAQ
What specific matters are being submitted to a vote of security holders?
The filing indicates that matters are being submitted to a vote, but the specific details of these matters are not provided in the provided text.
What are the key financial statements being filed?
The filing states that financial statements are being filed, but the specific content or period covered by these statements is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 26, 2024.
What is Seres Therapeutics, Inc.'s state of incorporation?
Seres Therapeutics, Inc. is incorporated in Delaware.
What is the address of Seres Therapeutics, Inc.'s principal executive offices?
The principal executive offices of Seres Therapeutics, Inc. are located at 101 Cambridgepark Drive, Cambridge, MA 02140.
Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2024-09-26 16:13:00
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share MCRB Nasdaq Global Select
Filing Documents
- d713439d8k.htm (8-K) — 33KB
- d713439dex991.htm (EX-99.1) — 8KB
- 0001193125-24-226929.txt ( ) — 163KB
- mcrb-20240926.xsd (EX-101.SCH) — 3KB
- mcrb-20240926_lab.xml (EX-101.LAB) — 17KB
- mcrb-20240926_pre.xml (EX-101.PRE) — 11KB
- d713439d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibits Exhibit No. Description 99.1 Press Release issued by Seres Therapeutics, Inc., dated September 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERES THERAPEUTICS, INC. Date: September 26, 2024 By: /s/ Eric D. Shaff Name: Eric D. Shaff Title: President and Chief Executive Officer